Cognitive dysfunction in depression – Pathophysiology and novel targets

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 10, 2014, Pages 1819-1835

  Carvalho, Andre F ^a   Miskowiak, Kamilla K ^b   Hyphantis, Thomas N ^c   Köhler, Cristiano A ^d   Alves, Gilberto S ^a   Bortolato, Beatrice ^e   Sales, Paulo Marcelo G ^a   Machado Vieira, Rodrigo ^f   Berk, Michael ^g,h   McIntyre, Roger S ⁱ  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b University of Copenhagen   (Denmark)

^c UNIVERSITY OF IOANNINA   (Greece)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^e UNIVERSITY OF PADOVA   (Italy)

^f NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^g DEAKIN UNIVERSITY   (Australia)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ UNIVERSITY OF TORONTO   (Canada)

Author keywords

Brain derived neurotrophic factor; Cognition; Cytokine; Erythropoietin; Inflammation; Major depressive disorder; Novel targets; Oxidative stress; S adenosyl L methionine

Indexed keywords

2, 4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLCYSTEINE; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHIN; CREATINE; CURCUMIN; EPICATECHIN; ERYTHROPOIETIN; FLUOXETINE; GAMMA INTERFERON; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOXYGENASE; LITHIUM; MELATONIN; MINOCYCLINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NITRIC OXIDE SYNTHASE; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN SYNTHASE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; S ADENOSYLMETHIONINE; SUPEROXIDE DISMUTASE; THIAZOLIDINE DERIVATIVE; TRYPTOPHAN 2, 3 DIOXYGENASE; UNCLASSIFIED DRUG; XANTHINE OXIDASE; NOOTROPIC AGENT;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; COGNITION; COGNITIVE DEFECT; DEPRESSION; DEXAMETHASONE SUPPRESSION TEST; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INFLAMMATION; KINDLING; MAJOR DEPRESSION; META ANALYSIS (TOPIC); MITOCHONDRIAL DYSFUNCTION; NERVOUS SYSTEM DEVELOPMENT; NEUROTRANSMISSION; NEUROTROPISM; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; RISK FACTOR; STRESS; COGNITION DISORDERS; COMPLICATION;

COGNITION DISORDERS; DEPRESSION; HUMANS; NOOTROPIC AGENTS;

EID: 84924088127     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527313666141130203627     Document Type: Article

References (257)

1. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health 2013; 34: 119-38.
2. Alonso J, Vilagut G, Adroher ND, et al. Disability mediates the impact of common conditions on perceived health. PloS One 2013; 8(6): e65858.
3. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163(1): 28-40.
4. Stotland NL. Recovery from depression. Psych Clin NA 2012; 35(1): 37-49.
5. Stewart WF, Ricci JA, Chee E, Hahn SR, Morganstein D. Cost of lost productive work time among US workers with depression. JAMA 2003; 289(23): 3135-44.
6. McIntyre RS, Cha DS, Soczynska JK, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depr Anxiety 2013; 30(6): 515-27.
7. Jaeger J, Berns S, Uzelac S, Davis-Conway S. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res 2006; 145(1): 39-48.
8. Buist-Bouwman MA, Ormel J, de Graaf R, et al. Mediators of the association between depression and role functioning. Acta Psychiatr Scand 2008; 118(6): 451-8.
9. Mowla A, Ashkani H, Ghanizadeh A, et al. Do memory complaints represent impaired memory performance in patients with major depressive disorder? Depr Anxiety 2008; 25(10): E92-6.
10. APA. Diagnostic and Statistical Manual for Mental Disorders, Fifth Edition. 5th ed.; Arlington VA: American Psychiatric Association; 2013.
11. WHO. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. 1st ed: World Health Organization; 1992.
12. Lahr D, Beblo T, Hartje W. Cognitive performance and subjective complaints before and after remission of major depression. Cogn Neuropsychiatry 2007; 12(1): 25-45.
13. Rohling ML, Green P, Allen LM 3rd, Iverson GL. Depressive symptoms and neurocognitive test scores in patients passing symptom validity tests. Arch Clin Neuropsychol 2002; 17(3): 205-22.
14. Ravnkilde B, Videbech P, Clemmensen K, et al. Cognitive deficits in major depression. Scand J Psychol 2002; 43(3): 239-51.
15. Porter RJ, Gallagher P, Thompson JM, Young AH. Neurocognitive impairment in drug-free patients with major depressive disorder. Br J Psychiatry 2003; 182: 214-20.
16. Landro NI, Stiles TC, Sletvold H. Neuropsychological function in nonpsychotic unipolar major depression. Neuropsychiatry Neuropsychol Behav Neurol 2001; 14(4): 233-40.
17. Keilp JG, Sackeim HA, Brodsky BS, et al. Neuropsychological dysfunction in depressed suicide attempters. Am J Psychiatry 2001; 158(5): 735-41.
18. Naismith SL, Hickie IB, Turner K, et al. Neuropsychological performance in patients with depression is associated with clinical, etiological and genetic risk factors. J Clin Exp Neuropsychol 2003; 25(6): 866-77.
19. Lampe IK, Sitskoorn MM, Heeren TJ. Effects of recurrent major depressive disorder on behavior and cognitive function in female depressed patients. Psychiatry Res 2004; 125(2): 73-9.
20. Simons CJ, Jacobs N, Derom C, et al. Cognition as predictor of current and follow-up depressive symptoms in the general population. Acta Psychiatr Scand 2009; 120(1): 45-52.
21. Fossati P, Coyette F, Ergis AM, Allilaire JF. Influence of age and executive functioning on verbal memory of inpatients with depression. J Affect Disord 2002; 68(2-3): 261-71.
22. Vythilingam M, Vermetten E, Anderson GM, et al. Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment. Biol Psychiatry 2004; 56(2): 101-12.
23. Herrera-Guzman I, Gudayol-Ferre E, Herrera-Guzman D, et al. Effects of selective serotonin reuptake and dual serotonergicnoradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. J Psychiatric Res 2009; 43(9): 855-63.
24. Wagner S, Doering B, Helmreich I, Lieb K, Tadic A. A metaanalysis of executive dysfunctions in unipolar major depressive disorder without psychotic symptoms and their changes during antidepressant treatment. Acta Psychiatr Scand 2012; 125(4): 281-92.
25. Marcos T, Salamero M, Gutierrez F, et al. Cognitive dysfunctions in recovered melancholic patients. J Affect Disord 1994; 32(2): 133-7.
26. Hasselbalch BJ, Knorr U, Kessing LV. Cognitive impairment in the remitted state of unipolar depressive disorder: a systematic review. J Affect Disord 2011; 134(1-3): 20-31.
27. Hasselbalch BJ, Knorr U, Hasselbalch SG, Gade A, Kessing LV. Cognitive deficits in the remitted state of unipolar depressive disorder. Neuropsychology 2012; 26(5): 642-51.
28. Yamamoto T, Shimada H. Cognitive dysfunctions after recovery from major depressive episodes. Appl Neuropsychol Adult 2012; 19(3): 183-91.
29. Bora E, Harrison BJ, Yucel M, Pantelis C. Cognitive impairment in euthymic major depressive disorder: a meta-analysis. Psychol Med 2013; 43(10): 2017-26.
30. Herrera-Guzman I, Gudayol-Ferre E, Herrera-Abarca JE, et al. Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recovery. J Affect Disord 2010; 123(1-3): 341-50.
31. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol 2014; 2014: 1-11.
32. Pearce EF, Murphy JA. Vortioxetine for the treatment of depression. Ann Pharmacother 2014; 48(6): 758-65.
33. Madhoo M, Keefe RS, Roth RM, et al. Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. Neuropsychopharmacology 2014; 39(6): 1388-98.
34. Moylan S, Maes M, Wray NR, Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry 2013; 18(5): 595-606.
35. Sapolsky RM. The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatry 2000; 48(8): 755-65.
36. McKinnon MC, Yucel K, Nazarov A, MacQueen GM. A metaanalysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. J Psychiatry Neurosci 2009; 34(1): 41-54.
37. Catena-Dell'Osso M, Bellantuono C, Consoli G, et al. Inflammatory and neurodegenerative pathways in depression: a new avenue for antidepressant development? Curr Med Chem 2011; 18(2): 245-55.
38. Videbech P, Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry 2004; 161(11): 1957-66.
39. Arnone D, McIntosh AM, Ebmeier KP, Munafo MR, Anderson IM. Magnetic resonance imaging studies in unipolar depression: systematic review and meta-regression analyses. Eur Neuropsychopharmacol 2012; 22(1): 1-16.
40. Bora E, Fornito A, Pantelis C, Yucel M. Gray matter abnormalities in Major Depressive Disorder: a meta-analysis of voxel based morphometry studies. J Affect Disord 2012; 138(1-2): 9-18.
41. Gao Y, Huang C, Zhao K, et al. Depression as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Int J Geriatr Psychiatry 2013; 28(5): 441-9.
42. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gener Psychiatry 2006; 63(5): 530-8.
43. Myint AM, Kim YK. Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med Hyp 2003; 61(5-6): 519-25.
44. Maes M, Yirmyia R, Noraberg J, et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metabol Brain Dis 2009; 24(1): 27-53.
45. Monroe SM, Simons AD. Diathesis-stress theories in the context of life stress research: implications for the depressive disorders. Psychol Bull 1991; 110(3): 406-25.
46. Flint J, Kendler KS. The genetics of major depression. Neuron 2014; 81(3): 484-503.
47. Willner P, Scheel-Kruger J, Belzung C. The neurobiology of depression and antidepressant action. Neurosci Biobehav Rev 2013; 37(10 Pt 1): 2331-71.
48. Juruena MF. Early-life stress and HPA axis trigger recurrent adulthood depression. Epilep Behav 2013; 38C: 148-159.
49. Roy A. Role of past loss in depression. Arch Gener Psychiatry 1981; 38(3): 301-2.
50. Slavich GM, Monroe SM, Gotlib IH. Early parental loss and depression history: associations with recent life stress in major depressive disorder. J Psychiatr Res 2011; 45(9): 1146-52.
51. Kendler KS, Gardner CO. Sex differences in the pathways to major depression: a study of opposite-sex twin pairs. Am J Psychiatry 2014; 171(4): 426-35.
52. Caspi A, Hariri AR, Holmes A, Uher R, Moffitt TE. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am J Psychiatry 2010; 167(5): 509-27.
53. Klengel T, Mehta D, Anacker C, et al. Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. Nat Neurosci 2013; 16(1): 33-41.
54. Weaver IC, Cervoni N, Champagne FA, et al. Epigenetic programming by maternal behavior. Nat Neurosci 2004; 7(8): 847-54.
55. Christensen MV, Kessing LV. Do personality traits predict first onset in depressive and bipolar disorder? Nord J Psychiatry 2006; 60(2): 79-88.
56. Fanous AH, Kendler KS. The genetic relationship of personality to major depression and schizophrenia. Neurotox Res 2004; 6(1): 43-50.
57. Bukh JD, Bock C, Vinberg M, Gether U, Kessing LV. Differences between early and late onset adult depression. Clin Pract Epidemiol Mental Health 2011; 7: 140-7.
58. Ormel J, Bastiaansen A, Riese H, et al. The biological and psychological basis of neuroticism: current status and future directions. Neurosci Biobehav Rev 2013; 37(1): 59-72.
59. Post RM. Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neurosci Biobehav Rev 2007; 31(6): 858-73.
60. Stroud CB, Davila J, Hammen C, Vrshek-Schallhorn S. Severe and nonsevere events in first onsets versus recurrences of depression: evidence for stress sensitization. J Abnormal Psychol 2011; 120(1): 142-54.
61. Neumeister A, Wood S, Bonne O, et al. Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects. Biol Psychiatry 2005; 57(8): 935-7.
62. Aizenstein HJ, Butters MA, Wu M, et al. Altered functioning of the executive control circuit in late-life depression: episodic and persistent phenomena. Am J Geriatr Psychiatry 2009; 17(1): 30-42.
63. Bhagwagar Z, Hinz R, Taylor M, et al. Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C]MDL 100, 907. Am J Psychiatry 2006; 163(9): 1580-7.
64. Bhagwagar Z, Wylezinska M, Jezzard P, et al. Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients. Int J Neuropsychopharmacol 2008; 11(2): 255-60.
65. Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 2003; 160(9): 1554-65.
66. Gould E, McEwen BS, Tanapat P, Galea LA, Fuchs E. Neurogenesis in the dentate gyrus of the adult tree shrew is regulated by psychosocial stress and NMDA receptor activation. J Neurosci 1997; 17(7): 2492-8.
67. de Quervain DJ, Roozendaal B, Nitsch RM, McGaugh JL, Hock C. Acute cortisone administration impairs retrieval of long-term declarative memory in humans. Nat Neurosci 2000; 3(4): 313-4.
68. Newcomer JW, Selke G, Melson AK, et al. Decreased memory performance in healthy humans induced by stress-level cortisol treatment. Arch Gener Psychiatry 1999; 56(6): 527-33.
69. McEwen BS, Morrison JH. The brain on stress: vulnerability and plasticity of the prefrontal cortex over the life course. Neuron 2013; 79(1): 16-29.
70. Hinwood M, Tynan RJ, Charnley JL, et al. Chronic stress induced remodeling of the prefrontal cortex: structural re-organization of microglia and the inhibitory effect of minocycline. Cerebr Cortex 2013; 23(8): 1784-97.
71. Liu RJ, Aghajanian GK. Stress blunts serotonin-and hypocretinevoked EPSCs in prefrontal cortex: role of corticosterone-mediated apical dendritic atrophy. Proc Natl Acad Sci USA 2008; 105(1): 359-64.
72. Dias-Ferreira E, Sousa JC, Melo I, et al. Chronic stress causes frontostriatal reorganization and affects decision-making. Science 2009; 325(5940): 621-5.
73. McEwen BS. Stress, sex, and neural adaptation to a changing environment: mechanisms of neuronal remodeling. Ann NY Acad Sci 2010; 1204(Suppl): E38-59.
74. Miracle AD, Brace MF, Huyck KD, Singler SA, Wellman CL. Chronic stress impairs recall of extinction of conditioned fear. Neurobiol Learn Mem 2006; 85(3): 213-8.
75. Yuen EY, Wei J, Liu W, et al. Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex. Neuron 2012; 73(5): 962-77.
76. Shea A, Walsh C, Macmillan H, Steiner M. Child maltreatment and HPA axis dysregulation: relationship to major depressive disorder and post traumatic stress disorder in females. Psychoneuroendocrinology 2005; 30(2): 162-78.
77. Zunszain PA, Anacker C, Cattaneo A, Carvalho LA, Pariante CM. Glucocorticoids, cytokines and brain abnormalities in depression. Progr Neuropsychopharmacol Biol Psychiatry 2011; 35(3): 722-9.
78. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000; 23(5): 477-501.
79. Belvederi Murri M, Pariante C, Mondelli V, et al. HPA axis and aging in depression: systematic review and meta-analysis. Psychoneuroendocrinology 2014; 41: 46-62.
80. Nemeroff CB, Widerlov E, Bissette G, et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984; 226(4680): 1342-4.
81. Nemeroff CB, Krishnan KR, Reed D, et al. Adrenal gland enlargement in major depression. A computed tomographic study. Arch Gener Psychiatry 1992; 49(5): 384-7.
82. Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001; 49(5): 391-404.
83. Carvalho LA, Pariante CM. In vitro modulation of the glucocorticoid receptor by antidepressants. Stress 2008; 11(6): 411-24.
84. Anacker C, Zunszain PA, Cattaneo A, et al. Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor. Mol Psychiatry 2011; 16(7): 738-50.
85. Oberlander TF, Weinberg J, Papsdorf M, et al. Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses. Epigenetics 2008; 3(2): 97-106.
86. Ladd CO, Huot RL, Thrivikraman KV, Nemeroff CB, Plotsky PM. Long-term adaptations in glucocorticoid receptor and mineralocorticoid receptor mRNA and negative feedback on the hypothalamo-pituitary-adrenal axis following neonatal maternal separation. Biol Psychiatry 2004; 55(4): 367-75.
87. Zannas AS, Binder EB. Gene-environment interactions at the FKBP5 locus: sensitive periods, mechanisms and pleiotropism. Genes Brain Behav 2014; 13(1): 25-37.
88. Zimmermann P, Bruckl T, Nocon A, et al. Interaction of FKBP5 gene variants and adverse life events in predicting depression onset: results from a 10-year prospective community study. Am J Psychiatry 2011; 168(10): 1107-16.
89. Homberg JR, Molteni R, Calabrese F, Riva MA. The serotonin-BDNF duo: Developmental implications for the vulnerability to psychopathology. Neurosci Biobehav Rev 2014; 43c: 35-47.
90. Mueller A, Armbruster D, Moser DA, et al. Interaction of serotonin transporter gene-linked polymorphic region and stressful life events predicts cortisol stress response. Neuropsychopharmacology 2011; 36(7): 1332-9.
91. Smith MA, Makino S, Kvetnansky R, Post RM. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci 1995; 15(3 Pt 1): 1768-77.
92. Sato H, Takahashi T, Sumitani K, Takatsu H, Urano S. Glucocorticoid Generates ROS to Induce Oxidative Injury in the Hippocampus, Leading to Impairment of Cognitive Function of Rats. J Clin Biochem Nutr 2010; 47(3): 224-32.
93. You JM, Yun SJ, Nam KN, et al. Mechanism of glucocorticoidinduced oxidative stress in rat hippocampal slice cultures. Can J Physiol Pharmacol 2009; 87(6): 440-7.
94. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006; 27(1): 24-31.
95. Maes M, Bosmans E, Suy E, et al. Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1 beta and soluble interleukin-2 receptor production. Acta Psychiatr Scand 1991; 84(4): 379-86.
96. Elenkov IJ, Chrousos GP. Stress system-organization, physiology and immunoregulation. Neuroimmunomodulation 2006; 13(5-6): 257-67.
97. Heiser P, Lanquillon S, Krieg JC, Vedder H. Differential modulation of cytokine production in major depressive disorder by cortisol and dexamethasone. Eur Neuropsychopharmacol 2008; 18(12): 860-70.
98. Dantzer R, O'Connor JC, Lawson MA, Kelley KW. Inflammationassociated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011; 36(3): 426-36.
99. Dantzer R. Cytokine, sickness behavior, and depression. Immunol Allergy Clin NA 2009; 29(2): 247-64.
100. Dunn AJ, Swiergiel AH, de Beaurepaire R. Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev 2005; 29(4-5): 891-909.
101. Liu Y, Ho RC, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord 2012; 139(3): 230-9.
102. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67(5): 446-57.
103. Udina M, Castellvi P, Moreno-Espana J, et al. Interferon-induced depression in chronic hepatitis C: a systematic review and metaanalysis. J Clin Psychiatry 2012; 73(8): 1128-38.
104. Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Progr Neuropsychopharmacol Biol Psychiatry 2011; 35(3): 664-75.
105. Musselman D, Royster EB, Wang M, et al. The impact of escitalopram on IL-2-induced neuroendocrine, immune, and behavioral changes in patients with malignant melanoma: preliminary findings. Neuropsychopharmacology 2013; 38(10): 1921-8.
106. Kreisel T, Frank MG, Licht T, et al. Dynamic microglial alterations underlie stress-induced depressive-like behavior and suppressed neurogenesis. Mol Psychiatry 2014; 19(6): 699-709.
107. Skaper SD, Facci L, Giusti P. Mast cells, glia and neuroinflammation: partners in crime? Immunology 2014; 141(3): 314-27.
108. Bufalino C, Hepgul N, Aguglia E, Pariante CM. The role of immune genes in the association between depression and inflammation: a review of recent clinical studies. Brain Behav Immunity 2013; 31: 31-47.
109. Celik C, Erdem M, Cayci T, et al. The association between serum levels of neopterin and number of depressive episodes of major depression. Progr Neuropsychopharmacol Biol Psychiatry 2010; 34(2): 372-5.
110. Maes M, Mihaylova I, Kubera M, Ringel K. Activation of cellmediated immunity in depression: association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression. Progr Neuropsychopharmacol Biol Psychiatry 2012; 36(1): 169-75.
111. Khairova RA, Machado-Vieira R, Du J, Manji HK. A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol 2009; 12(4): 561-78.
112. Hurley LL, Tizabi Y. Neuroinflammation, neurodegeneration, and depression. Neurotox Res 2013; 23(2): 131-44.
113. Gold PW, Licinio J, Pavlatou MG. Pathological parainflammation and endoplasmic reticulum stress in depression: potential translational targets through the CNS insulin, klotho and PPARgamma systems. Mol Psychiatry 2013; 18(2): 154-65.
114. Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R. The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2, 3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Progr Neuropsychopharmacol Biol Psychiatry 2011; 35(3): 702-21.
115. Anderson G, Maes M. Oxidative/Nitrosative Stress and Immunoinflammatory Pathways in Depression: Treatment Implications. Curr Pharm Des 2014; 20(23): 3812-47.
116. Maes M, Rief W. Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathway. Psychiatry Res 2012; 196(2-3): 243-9.
117. Luca M, Luca A, Calandra C. Accelerated aging in major depression: the role of nitro-oxidative stress. Oxid Med Cell Longev 2013; 2013: 230797.
118. Moylan S, Berk M, Dean OM, et al. Oxidative & nitrosative stress in depression: Why so much stress? Neurosci Biobehav Rev 2014; 45c: 46-62.
119. Talarowska M, Bobinska K, Zajaczkowska M, et al. Impact of oxidative/nitrosative stress and inflammation on cognitive functions in patients with recurrent depressive disorders. Med Sci Monit 2014; 20: 110-5.
120. Palta P, Samuel LJ, Miller ER, 3rd, Szanton SL. Depression and oxidative stress: results from a meta-analysis of observational studies. Psychosom Med 2014; 76(1): 12-9.
121. Berk M, Williams LJ, Jacka FN, et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med 2013; 11: 200.
122. Zhou J, Zhang S, Zhao X, Wei T. Melatonin impairs NADPH oxidase assembly and decreases superoxide anion production in microglia exposed to amyloid-beta1-42. J Pineal Res 2008; 45(2): 157-65.
123. Seo JS, Park JY, Choi J, et al. NADPH oxidase mediates depressive behavior induced by chronic stress in mice. J Neurosci 2012; 32(28): 9690-9.
124. Michel TM, Camara S, Tatschner T, et al. Increased xanthine oxidase in the thalamus and putamen in depression. World J Biol Psychiatry 2010; 11(2 Pt 2): 314-20.
125. Herken H, Gurel A, Selek S, et al. Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. Arch Med Res 2007; 38(2): 247-52.
126. Galecki P, Talarowska M, Bobinska K, Szemraj J. COX-2 gene expression is correlated with cognitive function in recurrent depressive disorder. Psychiatry Res 2014; 215(2): 488-90.
127. Cassano P, Hidalgo A, Burgos V, Adris S, Argibay P. Hippocampal upregulation of the cyclooxygenase-2 gene following neonatal clomipramine treatment (a model of depression). Pharmacogenom J 2006; 6(6): 381-7.
128. Talarowska M, Galecki P, Maes M, et al. Nitric oxide plasma concentration associated with cognitive impairment in patients with recurrent depressive disorder. Neurosci Lett 2012; 510(2): 127-31.
129. Gao SF, Lu YR, Shi LG, et al. Nitric oxide synthase and nitric oxide alterations in chronically stressed rats: A model for nitric oxide in major depressive disorder. Psychoneuroendocrinology 2014; 47: 136-40.
130. Tomaz VS, Cordeiro RC, Costa AM, et al. Antidepressant-like effect of nitric oxide synthase inhibitors and sildenafil against lipopolysaccharide-induced depressive-like behavior in mice. Neuroscience 2014; 268: 236-46.
131. Akpinar A, Yaman GB, Demirdas A, Onal S. Possible role of adrenomedullin and nitric oxide in major depression. Progr Neuropsychopharmacol Biol Psychiatry 2013; 46: 120-5.
132. Aktan F. iNOS-mediated nitric oxide production and its regulation. Life Sci 2004; 75(6): 639-53.
133. Galecki P, Galecka E, Maes M, et al. The expression of genes encoding for COX-2, MPO, iNOS, and sPLA2-IIA in patients with recurrent depressive disorder. J Affect Disord 2012; 138(3): 360-6.
134. Montezuma K, Biojone C, Lisboa SF, et al. Inhibition of iNOS induces antidepressant-like effects in mice: pharmacological and genetic evidence. Neuropharmacology 2012; 62(1): 485-91.
135. Srivastava N, Barthwal MK, Dalal PK, et al. A study on nitric oxide, beta-adrenergic receptors and antioxidant status in the polymorphonuclear leukocytes from the patients of depression. J Affect Disord 2002; 72(1): 45-52.
136. Ikenouchi-Sugita A, Yoshimura R, Hori H, et al. Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: comparison between milnacipran and paroxetine. Progr Neuropsychopharmacol Biol Psychiatry 2009; 33(8): 1451-3.
137. Oliveira RM, Guimaraes FS, Deakin JF. Expression of neuronal nitric oxide synthase in the hippocampal formation in affective disorders. Braz J Med Biol Res 2008; 41(4): 333-41.
138. Maes M, Kubera M, Mihaylova I, et al. Increased autoimmune responses against auto-epitopes modified by oxidative and nitrosative damage in depression: implications for the pathways to chronic depression and neuroprogression. J Affect Disord 2013; 149(1-3): 23-9.
139. Cumurcu BE, Ozyurt H, Etikan I, Demir S, Karlidag R. Total antioxidant capacity and total oxidant status in patients with major depression: impact of antidepressant treatment. Psychiatry Clin Neurosci 2009; 63(5): 639-45.
140. Stefanescu C, Ciobica A. The relevance of oxidative stress status in first episode and recurrent depression. J Affect Disord 2012; 143(1-3): 34-8.
141. Sarandol A, Sarandol E, Eker SS, et al. Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum Psychopharmacol 2007; 22(2): 67-73.
142. Galecki P, Kedziora J, Florkowski A, Galecka E. Lipid peroxidation and copper-zinc superoxide dismutase activity in patients treated with fluoxetine during the first episode of depression. Psychiatr Polsk 2007; 41(5): 615-24.
143. Talarowska M, Szemraj J, Galecki P. Myeloperoxidase gene expression and cognitive functions in depression. Adv Med Sci 2014; 60(1): 1-5.
144. Zell R, Geck P, Werdan K, Boekstegers P. TNF-alpha and IL-1 alpha inhibit both pyruvate dehydrogenase activity and mitochondrial function in cardiomyocytes: evidence for primary impairment of mitochondrial function. Mol Cell Biochem 1997; 177(1-2): 61-7.
145. Oxenkrug G, Ratner R. N-acetylserotonin and aging-associated cognitive impairment and depression. Aging Dis 2012; 3(4): 330-8.
146. Jang SW, Liu X, Pradoldej S, et al. N-acetylserotonin activates TrkB receptor in a circadian rhythm. Proc Natl Acad Sci USA 2010; 107(8): 3876-81.
147. Rigucci S, Serafini G, Pompili M, Kotzalidis GD, Tatarelli R. Anatomical and functional correlates in major depressive disorder: the contribution of neuroimaging studies. World J Biol Psychiatry 2010; 11(2 Pt 2): 165-80.
148. Gardner A, Johansson A, Wibom R, et al. Alterations of mitochondrial function and correlations with personality traits in selected major depressive disorder patients. J Affect Disord 2003; 76(1-3): 55-68.
149. Voloboueva LA, Giffard RG. Inflammation, mitochondria, and the inhibition of adult neurogenesis. J Neurosci Res 2011; 89(12): 1989-96.
150. Chakravarty S, Reddy BR, Sudhakar SR, et al. Chronic unpredictable stress (CUS)-induced anxiety and related mood disorders in a zebrafish model: altered brain proteome profile implicates mitochondrial dysfunction. PloS One 2013; 8(5): e63302.
151. Marazziti D, Baroni S, Picchetti M, et al. Mitochondrial alterations and neuropsychiatric disorders. Curr Med Chem 2011; 18(30): 4715-21.
152. Chen F, Wegener G, Madsen TM, Nyengaard JR. Mitochondrial plasticity of the hippocampus in a genetic rat model of depression after antidepressant treatment. Synapse 2013; 67(3): 127-34.
153. Della FP, Abelaira HM, Reus GZ, et al. Treatment with tianeptine induces antidepressive-like effects and alters the neurotrophin levels, mitochondrial respiratory chain and cycle Krebs enzymes in the brain of maternally deprived adult rats. Metab Brain Dis 2013; 28(1): 93-105.
154. Bonora M, De Marchi E, Patergnani S, et al. Tumor necrosis factor-alpha impairs oligodendroglial differentiation through a mitochondria-dependent process. Cell Death Differ 2014; 21(8): 1198-208.
155. Michel TM, Frangou S, Thiemeyer D, et al. Evidence for oxidative stress in the frontal cortex in patients with recurrent depressive disorder-a postmortem study. Psychiatry Res 2007; 151(1-2): 145-50.
156. Yi S, Nanri A, Matsushita Y, et al. Depressive symptoms and oxidative DNA damage in Japanese municipal employees. Psychiatry Res 2012; 200(2-3): 318-22.
157. Maes M, Mihaylova I, Kubera M, et al. Increased 8-hydroxydeoxyguanosine, a marker of oxidative damage to DNA, in major depression and myalgic encephalomyelitis/chronic fatigue syndrome. Neuroendocrinol Lett 2009; 30(6): 715-22.
158. Iseme RA, McEvoy M, Kelly B, et al. Autoantibodies and depression: evidence for a causal link? Neurosci Biobehav Rev 2014; 40: 62-79.
159. Christian KM, Song H, Ming GL. Functions and dysfunctions of adult hippocampal neurogenesis. Annu Rev Neurosci 2014; 37: 243-62.
160. Brunoni AR, Lopes M, Fregni F. A systematic review and metaanalysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008; 11(8): 1169-80.
161. Takebayashi M, Hashimoto R, Hisaoka K, Tsuchioka M, Kunugi H. Plasma levels of vascular endothelial growth factor and fibroblast growth factor 2 in patients with major depressive disorders. J Neural Transm 2010; 117(9): 1119-22.
162. Sievers C, Auer MK, Klotsche J, et al. IGF-I levels and depressive disorders: results from the Study of Health in Pomerania (SHIP). Eur Neuropsychopharmacol 2014; 24(6): 890-6.
163. Hock C, Heese K, Muller-Spahn F, et al. Increased cerebrospinal fluid levels of neurotrophin 3 (NT-3) in elderly patients with major depression. Mol Psychiatry 2000; 5(5): 510-3.
164. Turner CA, Watson SJ, Akil H. The fibroblast growth factor family: neuromodulation of affective behavior. Neuron 2012; 76(1): 160-74.
165. Rothermundt M, Arolt V, Wiesmann M, et al. S-100B is increased in melancholic but not in non-melancholic major depression. J Affect Disord 2001; 66(1): 89-93.
166. Gos T, Schroeter ML, Lessel W, et al. S100B-immunopositive astrocytes and oligodendrocytes in the hippocampus are differentially afflicted in unipolar and bipolar depression: a postmortem study. J Psychiatric Res 2013; 47(11): 1694-9.
167. Tseng PT, Lee Y, Lin PY. Age-associated decrease in serum glial cell line-derived neurotrophic factor levels in patients with major depressive disorder. Progr Neuropsychopharmacol Biol Psychiatry 2013; 40: 334-9.
168. Zhou W, Wang N, Yang C, et al. Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex. Eur Psychiatry. 2014; 29(7): 419-23.
169. Larsen MH, Mikkelsen JD, Hay-Schmidt A, Sandi C. Regulation of brain-derived neurotrophic factor (BDNF) in the chronic unpredictable stress rat model and the effects of chronic antidepressant treatment. J Psychiatr Res 2010; 44(13): 808-16.
170. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003; 301(5634): 805-9.
171. Lee BH, Kim H, Park SH, Kim YK. Decreased plasma BDNF level in depressive patients. J Affect Disord 2007; 101(1-3): 239-44.
172. Molendijk ML, Spinhoven P, Polak M, et al. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484). Mol Psychiatry 2014; 19(7): 791-800.
173. Soczynska JK, Mansur RB, Brietzke E, et al. Novel therapeutic targets in depression: minocycline as a candidate treatment. Behav Brain Res 2012; 235(2): 302-17.
174. Ahuja M, Bishnoi M, Chopra K. Protective effect of minocycline, a semi-synthetic second-generation tetracycline against 3-nitropropionic acid (3-NP)-induced neurotoxicity. Toxicology 2008; 244(2-3): 111-22.
175. Schildknecht S, Pape R, Muller N, et al. Neuroprotection by minocycline caused by direct and specific scavenging of peroxynitrite. J Biol Chem 2011; 286(7): 4991-5002.
176. Kim SS, Kong PJ, Kim BS, et al. Inhibitory action of minocycline on lipopolysaccharide-induced release of nitric oxide and prostaglandin E2 in BV2 microglial cells. Arch Pharmacol Res 2004; 27(3): 314-8.
177. Orio L, Llopis N, Torres E, et al. A study on the mechanisms by which minocycline protects against MDMA ('ecstasy')-induced neurotoxicity of 5-HT cortical neurons. Neurotox Res 2010; 18(2): 187-99.
178. Zhu F, Zheng Y, Ding YQ, et al. Minocycline and risperidone prevent microglia activation and rescue behavioral deficits induced by neonatal intrahippocampal injection of lipopolysaccharide in rats. PloS One 2014; 9(4): e93966.
179. Kernt M, Neubauer AS, Eibl KH, et al. Minocycline is cytoprotective in human trabecular meshwork cells and optic nerve head astrocytes by increasing expression of XIAP, survivin, and Bcl-2. Clin Ophthalmol 2010; 4: 591-604.
180. Mello BS, Monte AS, McIntyre RS, et al. Effects of doxycycline on depressive-like behavior in mice after lipopolysaccharide (LPS) administration. J Psychiatr Res 2013; 47(10): 1521-9.
181. Siopi E, Llufriu-Daben G, Fanucchi F, et al. Evaluation of late cognitive impairment and anxiety states following traumatic brain injury in mice: the effect of minocycline. Neurosci Lett 2012; 511(2): 110-5.
182. Borre Y, Sir V, de Kivit S, et al. Minocycline restores spatial but not fear memory in olfactory bulbectomized rats. Eur J Pharmacol 2012; 697(1-3): 59-64.
183. Levkovitz Y, Mendlovich S, Riwkes S, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010; 71(2): 138-49.
184. Nakasujja N, Miyahara S, Evans S, et al. Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment. Neurology 2013; 80(2): 196-202.
185. Sacktor N, Miyahara S, Deng L, et al. Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology 2011; 77(12): 1135-42.
186. Pasco JA, Jacka FN, Williams LJ, et al. Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression. Psychother Psychosomat 2010; 79(5): 323-5.
187. Stafford L, Berk M. The use of statins after a cardiac intervention is associated with reduced risk of subsequent depression: proof of concept for the inflammatory and oxidative hypotheses of depression? J Clin Psychiatry 2011; 72(9): 1229-35.
188. O'Neil A, Sanna L, Redlich C, et al. The impact of statins on psychological wellbeing: a systematic review and meta-analysis. BMC Med 2012; 10: 154.
189. Parsaik AK, Singh B, Hassan Murad M, et al. Statins use and risk of depression: a systematic review and meta-analysis. J Affect Disord 2014; 160: 62-7.
190. Lin PY, Chang AY, Lin TK. Simvastatin treatment exerts antidepressant-like effect in rats exposed to chronic mild stress. Pharmacol Biochem Behav 2014; 124c: 174-9.
191. Kilic FS, Ozatik Y, Kaygisiz B, Baydemir C, Erol K. Acute antidepressant and anxiolytic effects of simvastatin and its mechanisms in rats. Neurosciences 2012; 17(1): 39-43.
192. Cimino M, Balduini W, Carloni S, et al. Neuroprotective effect of simvastatin in stroke: a comparison between adult and neonatal rat models of cerebral ischemia. Neurotoxicology 2005; 26(5): 929-33.
193. Sironi L, Banfi C, Brioschi M, et al. Activation of NF-kB and ERK1/2 after permanent focal ischemia is abolished by simvastatin treatment. Neurobiol Dis 2006; 22(2): 445-51.
194. Ludka FK, Zomkowski AD, Cunha MP, et al. Acute atorvastatin treatment exerts antidepressant-like effect in mice via the Larginine-nitric oxide-cyclic guanosine monophosphate pathway and increases BDNF levels. Eur Neuropsychopharmacol 2013; 23(5): 400-12.
195. Swiger KJ, Manalac RJ, Blumenthal RS, Blaha MJ, Martin SS. Statins and cognition: a systematic review and meta-analysis of short-and long-term cognitive effects. Mayo Clin Proc 2013; 88(11): 1213-21.
196. van der Vaart T, Plasschaert E, Rietman AB, et al. Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial. Lancet Neurol 2013; 12(11): 1076-83.
197. Krab LC, de Goede-Bolder A, Aarsen FK, et al. Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial. JAMA 2008; 300(3): 287-94.
198. Ghanizadeh A, Hedayati A. Augmentation of fluoxetine with lovastatin for treating major depressive disorder, a randomized double-blind placebo controlled-clinical trial. Depress Anxiety 2013; 30(11): 1084-8.
199. Galecki P, Szemraj J, Bienkiewicz M, Zboralski K, Galecka E. Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. Human Psychopharmacol 2009; 24(4): 277-86.
200. Wang Y, Yang F, Liu YF, Gao F, Jiang W. Acetylsalicylic acid as an augmentation agent in fluoxetine treatment resistant depressive rats. Neurosci Lett 2011; 499(2): 74-9.
201. Kim SW, Jeong JY, Kim HJ, et al. Combination treatment with ethyl pyruvate and aspirin enhances neuroprotection in the postischemic brain. Neurotox Res 2010; 17(1): 39-49.
202. Wang YP, Wu Y, Li LY, et al. Aspirin-triggered lipoxin A4 attenuates LPS-induced pro-inflammatory responses by inhibiting activation of NF-kappaB and MAPKs in BV-2 microglial cells. J Neuroinflammation 2011; 8: 95.
203. Price JF, Stewart MC, Deary IJ, et al. Low dose aspirin and cognitive function in middle aged to elderly adults: randomised controlled trial. Br Med J 2008; 337: a1198.
204. Na KS, Lee KJ, Lee JS, Cho YS, Jung HY. Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis. Progr Neuropsychopharmacol Biol Psychiatry 2014; 48: 79-85.
205. Faridhosseini F, Sadeghi R, Farid L, Pourgholami M. Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebocontrolled trials. Hum Psychopharmacol 2014; 29(3): 216-23.
206. Krishnan R, Cella D, Leonardi C, et al. Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks. Br J Dermatol 2007; 157(6): 1275-7.
207. Bayramgurler D, Karson A, Ozer C, Utkan T. Effects of long-term etanercept treatment on anxiety-and depression-like neurobehaviors in rats. Physiol Behav 2013; 119: 145-8.
208. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013; 70(1): 31-41.
209. Berk M, Malhi GS, Gray LJ, Dean OM. The promise of Nacetylcysteine in neuropsychiatry. Trends Pharmacol Sci 2013; 34(3): 167-77.
210. Dodd S, Dean O, Copolov DL, Malhi GS, Berk M. Nacetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin Biol Ther 2008; 8(12): 1955-62.
211. Nicoletti VG, Marino VM, Cuppari C, et al. Effect of antioxidant diets on mitochondrial gene expression in rat brain during aging. Neurochem Res 2005; 30(6-7): 737-52.
212. Noble M, Mayer-Proschel M. On the track of cell survival pharmaceuticals in the oligodendrocyte type-2 astrocyte lineage. Persp Devel Neurobiol 1996; 3(2): 121-31.
213. Smaga I, Pomierny B, Krzyzanowska W, et al. N-acetylcysteine possesses antidepressant-like activity through reduction of oxidative stress: behavioral and biochemical analyses in rats. Progr Neuropsychopharmacol Biol Psychiatry 2012; 39(2): 280-7.
214. Goncalves JF, Fiorenza AM, Spanevello RM, et al. Nacetylcysteine prevents memory deficits, the decrease in acetylcholinesterase activity and oxidative stress in rats exposed to cadmium. Chem Biol Inter 2010; 186(1): 53-60.
215. Cao L, Li L, Zuo Z. N-acetylcysteine reverses existing cognitive impairment and increased oxidative stress in glutamate transporter type 3 deficient mice. Neuroscience 2012; 220: 85-9.
216. Berk M, Dean OM, Cotton SM, et al. The efficacy of adjunctive Nacetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 2014; 75(6): 628-36.
217. Hoffer ME, Balaban C, Slade MD, Tsao JW, Hoffer B. Amelioration of acute sequelae of blast induced mild traumatic brain injury by N-acetyl cysteine: a double-blind, placebo controlled study. PloS One 2013; 8(1): e54163.
218. Dean OM, Bush AI, Copolov DL, et al. Effects of N-acetyl cysteine on cognitive function in bipolar disorder. Psychiatry Clin Neurosci 2012; 66(6): 514-7.
219. Ding K, Wang H, Xu J, et al. Melatonin stimulates antioxidant enzymes and reduces oxidative stress in experimental traumatic brain injury: the Nrf2-ARE signaling pathway as a potential mechanism. Free Radic Biol Med 2014; 73c: 1-11.
220. Bhattacharya P, Pandey AK, Paul S, Patnaik R. Melatonin renders neuroprotection by protein kinase C mediated aquaporin-4 inhibition in animal model of focal cerebral ischemia. Life Sci 2014; 100(2): 97-109.
221. Juan WS, Huang SY, Chang CC, et al. Melatonin improves neuroplasticity by upregulating the growth-associated protein-43 (GAP-43) and NMDAR postsynaptic density-95 (PSD-95) proteins in cultured neurons exposed to glutamate excitotoxicity and in rats subjected to transient focal cerebral ischemia even during a longterm recovery period. J Pineal Res 2014; [Epub ahead of print].
222. Carloni S, Albertini MC, Galluzzi L, et al. Melatonin reduces endoplasmic reticulum stress and preserves sirtuin 1 expression in neuronal cells of newborn rats after hypoxia-ischemia. J Pineal Res 2014; 57(2): 192-9.
223. Fava M, Targum SD, Nierenberg AA, et al. An exploratory study of combination buspirone and melatonin SR in major depressive disorder (MDD): a possible role for neurogenesis in drug discovery. J Psychiatr Res 2012; 46(12): 1553-63.
224. McIntyre RS, Kenna HA, Nguyen HT, et al. Brain volume abnormalities and neurocognitive deficits in diabetes mellitus: points of pathophysiological commonality with mood disorders? Adv Ther 2010; 27(2): 63-80.
225. McIntyre RS, Powell AM, Kaidanovich-Beilin O, et al. The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders. Behav Brain Res 2013; 237: 164-71.
226. McIntyre RS, Soczynska JK, Woldeyohannes HO, et al. Thiazolidinediones: novel treatments for cognitive deficits in mood disorders? Expert Opin Pharmacother 2007; 8(11): 1615-28.
227. Sepanjnia K, Modabbernia A, Ashrafi M, Modabbernia MJ, Akhondzadeh S. Pioglitazone adjunctive therapy for moderate-tosevere major depressive disorder: randomized double-blind placebo-controlled trial. Neuropsychopharmacology 2012; 37(9): 2093-100.
228. Marti HH, Wenger RH, Rivas LA, et al. Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 1996; 8(4): 666-76.
229. Sargin D, Friedrichs H, El-Kordi A, Ehrenreich H. Erythropoietin as neuroprotective and neuroregenerative treatment strategy: comprehensive overview of 12 years of preclinical and clinical research. Best Pract Res Clin Anaesthesiol 2010; 24(4): 573-94.
230. Miskowiak K, Inkster B, O'Sullivan U, et al. Differential effects of erythropoietin on neural and cognitive measures of executive function 3 and 7 days post-administration. Exper Brain Res 2008; 184(3): 313-21.
231. Miskowiak K, O'Sullivan U, Harmer CJ. Erythropoietin enhances hippocampal response during memory retrieval in humans. J Neurosci 2007; 27(11): 2788-92.
232. Miskowiak KW, Vinberg M, Christensen EM, et al. Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial. Neuropsychopharmacology 2014; 39(6): 1399-408.
233. Lauritzen I, Blondeau N, Heurteaux C, et al. Polyunsaturated fatty acids are potent neuroprotectors. EMBO J 2000; 19(8): 1784-93.
234. Zhang W, Hu X, Yang W, Gao Y, Chen J. Omega-3 polyunsaturated fatty acid supplementation confers long-term neuroprotection against neonatal hypoxic-ischemic brain injury through anti-inflammatory actions. Stroke 2010; 41(10): 2341-7.
235. Grosso G, Pajak A, Marventano S, et al. Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PloS One 2014; 9(5): e96905.
236. Mazereeuw G, Lanctot KL, Chau SA, Swardfager W, Herrmann N. Effects of omega-3 fatty acids on cognitive performance: a metaanalysis. Neurobiol Aging 2012; 33(7): 1482. e17-29.
237. Lopresti AL, Hood SD, Drummond PD. Multiple antidepressant potential modes of action of curcumin: a review of its antiinflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects. J Psychopharmacol 2012; 26(12): 1512-24.
238. Xie L, Li XK, Funeshima-Fuji N, et al. Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production. Int Immunopharmacol 2009; 9(5): 575-81.
239. Zhang M, Deng CS, Zheng JJ, Xia J. Curcumin regulated shift from Th1 to Th2 in trinitrobenzene sulphonic acid-induced chronic colitis. Acta Pharmacol Sin 2006; 27(8): 1071-7.
240. Dong S, Zeng Q, Mitchell ES, et al. Curcumin enhances neurogenesis and cognition in aged rats: implications for transcriptional interactions related to growth and synaptic plasticity. PloS One 2012; 7(2): e31211.
241. Bergman J, Miodownik C, Bersudsky Y, et al. Curcumin as an addon to antidepressive treatment: a randomized, double-blind, placebo-controlled, pilot clinical study. Clin Neuropharmacol 2013; 36(3): 73-7.
242. Sanmukhani J, Satodia V, Trivedi J, et al. Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. Phytother Res 2014; 28(4): 579-85.
243. Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. Sadenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry 2010; 167(8): 942-8.
244. Levkovitz Y, Alpert JE, Brintz CE, Mischoulon D, Papakostas GI. Effects of S-adenosylmethionine augmentation of serotoninreuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. J Affect Disord 2012; 136(3): 1174-8.
245. Sokolov AN, Pavlova MA, Klosterhalfen S, Enck P. Chocolate and the brain: neurobiological impact of cocoa flavanols on cognition and behavior. Neurosci Biobehav Rev 2013; 37(10 Pt 2): 2445-53.
246. Mohamed RH, Karam RA, Amer MG. Epicatechin attenuates doxorubicin-induced brain toxicity: critical role of TNF-alpha, iNOS and NF-kappaB. Brain Res Bull 2011; 86(1-2): 22-8.
247. Wirtz PH, von Kanel R, Meister RE, et al. Dark chocolate intake buffers stress reactivity in humans. J Am Coll Cardiol 2014; 63(21): 2297-9.
248. Nierenberg AA, Kansky C, Brennan BP, et al. Mitochondrial modulators for bipolar disorder: a pathophysiologically informed paradigm for new drug development. Austr NZ J Psychiatry 2013; 47(1): 26-42.
249. Adcock KH, Nedelcu J, Loenneker T, et al. Neuroprotection of creatine supplementation in neonatal rats with transient cerebral hypoxia-ischemia. Devel Neurosci 2002; 24(5): 382-8.
250. McMorris T, Harris RC, Swain J, et al. Effect of creatine supplementation and sleep deprivation, with mild exercise, on cognitive and psychomotor performance, mood state, and plasma concentrations of catecholamines and cortisol. Psychopharmacology 2006; 185(1): 93-103.
251. Roitman S, Green T, Osher Y, Karni N, Levine J. Creatine monohydrate in resistant depression: a preliminary study. Bipol Disord 2007; 9(7): 754-8.
252. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipol Disord 2013; 15(1): 1-44.
253. Carvalho AF, Berk M, Hyphantis TN, McIntyre RS. The integrative management of treatment-resistant depression: a comprehensive review and perspectives. Psychother Psychosomat 2014; 83(2): 70-88.
254. Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ (Clinical research ed) 2013; 346: f3646.
255. Mauer S, Vergne D, Ghaemi SN. Standard and trace-dose lithium: A systematic review of dementia prevention and other behavioral benefits. Austr NZ J Psychiatry 2014; 48(9): 809-18.
256. Hajek T, Kopecek M, Hoschl C, Alda M. Smaller hippocampal volumes in patients with bipolar disorder are masked by exposure to lithium: a meta-analysis. J Psychiatr Neurosci 2012; 37(5): 333-43.
257. Malhi GS, Tanious M, Das P, Coulston CM, Berk M. Potential mechanisms of action of lithium in bipolar disorder. Curr Underst CNS Drugs 2013; 27(2): 135-53.